Figitumumab,Abbexa,abx831165
Figitumumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IGF1R/CD221, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
Host
Human
Reactivity
Human
Application
ELISA, WB
Conjugate
Unconjugated
Platform ID
BAB674670930
Abbexa
Contact
Tel: +44 (0) 1223 755950
Fax: +44 (0) 1223 755951
Email:
Product Specifications
Specifications
NameFigitumumab
Cat. No.abx831165
HostHuman
IsotypeIgG2 Kappa
ReactivityHuman
ConjugationUnconjugated
ApplicationELISA, WB
Working DilutionsOptimal dilutions/concentrations should be determined by the end user.
ClonalityMonoclonal
ConcentrationBatch-dependent, typically between 0.5-2.0 mg/ml.
TargetIGF1R/CD221
PurityPurified from cell culture supernatants by Protein A/G chromatography.
Appearance/FormLiquid
Formulation0.01 M PBS. pH 7.4.
StorageAliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Regulatory StatusResearch Use Only
Category Paths
- Products>Primary Antibodies>Biosimilar Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.